SocGen Debuts Trade Repository Reporting Service

city of london
A large percentage of European OTC trade runs through London, presently, and is also the location of many repositories.

The facility has been launch in line with European Market Infrastructure Regulation (EMIR) provisions regarding the reporting of these trades, in which both counterparties must report to a repository. Several large banks are now offering so-called "delegated reporting" services to clients, whereby the bank will report to the repository on their behalf.

SGSS will report these trades to the trpository run by the Depository Trust and Clearing Corporation, which has emerged as one of the largest facilities of its kind in the wake of mandatory reporting.

"New requirements demand a new industry mindset. Firms using OTC derivatives need to adapt their operational set-up by developing their own trade repository reporting capabilities or by mandating an asset servicer that can report on their behalf," says Emmanuelle Choukroun, director of new services for asset managers and asset owners at SGSS. "The appointment of a well equipped services provider can help OTC derivatives users ─ whether institutional investors or asset managers ─ adapt to the new regulatory landscape quickly, cost-effectively and safely."

 

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Waters Wrap: The tough climb for startups

Anthony speaks with two seasoned technologists to better understand why startups have such a tough time getting banks and asset managers to sign on the dotted line.

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here